Journal of thrombosis and haemostasis : JTH · 2026
Plasma levels of adiponectin and risk of future incident venous thromboembolism.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Onsaker Asbjørn L, van Hylckama Vlieg Astrid, Ueland Thor, Aukrust Pål, Brækkan Sigrid K, Hansen John-Bjarne, Morelli Vânia M
Аннотация
BACKGROUND: Adiponectin, a hormone-like protein primarily secreted by adipocytes, is typically decreased in obesity. Adiponectin has been shown to have antithrombotic properties through regulation of hemostatic factors in vitro. However, the association between adiponectin and venous thromboembolism (VTE) remains unclear.
OBJECTIVES: To investigate the association between plasma adiponectin levels and risk of future first lifetime VTE.
METHODS: A population-based nested case-control study, including 381 VTE cases and 772 age-and sex-matched controls, was derived from the Tromsø4 survey (1994/95-2007). Adiponectin was measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across adiponectin quartiles (Q) determined in controls using sex-specific quartile cut-offs. To investigate short-term associations, time-restricted analysis was performed including VTE cases occurring up to 5 years after cohort inclusion.
RESULTS: High adiponectin levels were associated with decreased VTE risk, with an OR of 0.69 (95% CI 0.48-0.99) for Q4 vs Q1 (reference) in age- and sex-adjusted analysis for the entire study period. The inverse association between adiponectin and VTE risk was stronger with analysis restricted to the first 5 years after cohort inclusion, with an OR of 0.40 (95% CI 0.20-0.77) for Q4 vs Q1. The additional adjustment for body mass index and C-reactive protein had minor impact on risk estimates.
CONCLUSION: Our results suggest that high plasma adiponectin levels are associated with decreased risk of future first lifetime VTE, particularly shortly after cohort inclusion, and that adiponectin might play a role in the pathogenesis of VTE.
OBJECTIVES: To investigate the association between plasma adiponectin levels and risk of future first lifetime VTE.
METHODS: A population-based nested case-control study, including 381 VTE cases and 772 age-and sex-matched controls, was derived from the Tromsø4 survey (1994/95-2007). Adiponectin was measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across adiponectin quartiles (Q) determined in controls using sex-specific quartile cut-offs. To investigate short-term associations, time-restricted analysis was performed including VTE cases occurring up to 5 years after cohort inclusion.
RESULTS: High adiponectin levels were associated with decreased VTE risk, with an OR of 0.69 (95% CI 0.48-0.99) for Q4 vs Q1 (reference) in age- and sex-adjusted analysis for the entire study period. The inverse association between adiponectin and VTE risk was stronger with analysis restricted to the first 5 years after cohort inclusion, with an OR of 0.40 (95% CI 0.20-0.77) for Q4 vs Q1. The additional adjustment for body mass index and C-reactive protein had minor impact on risk estimates.
CONCLUSION: Our results suggest that high plasma adiponectin levels are associated with decreased risk of future first lifetime VTE, particularly shortly after cohort inclusion, and that adiponectin might play a role in the pathogenesis of VTE.